ADC Therapeutics

ADCT

Market cap $525M

LAUSANNE, Switzerland , Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 47,000 of the Company's common shares to two new employees on December 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADC Therapeutics SA ( ADCT ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Nicole Riley Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Jose Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q3 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.42 per share a year ago.

Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA®  plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028 LAUSANNE, Switzerland , Nov. 10, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates. "The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA ®  as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

LAUSANNE, Switzerland , Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, November 10, 2025, at 8:30 a.m. EST to report financial results for the third quarter of 2025 and provide operational updates.

LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November: Stephens Biotechnology Virtual Fireside Chats 2025Date: November 3, 2025 Presentation Time: 12:00 p.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Virtual There will not be a replay or transcript of the call.

LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 11.3 million common shares at $4.00 per share and pre-funded warrants to purchase 3.8 million common shares at $3.90 per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.

LAUSANNE, Switzerland , Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 162,000 of the Company's common shares to four new employees on October 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.